Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Nucana ( (NCNA) ) is now available.
On June 5, 2025, NuCana plc announced the publication of its 2024 UK Annual Report and distributed a notice for its upcoming annual general meeting scheduled for June 27, 2025. The company also coordinated with Citibank to facilitate voting for American Depositary Shares holders, though practical and legal limitations may affect the voting process. This announcement is significant as it outlines the company’s recent financial performance and strategic decisions, providing insights into its future direction and engagement with shareholders.
The most recent analyst rating on (NCNA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a biopharmaceutical company based in the United Kingdom, focusing on the development of novel cancer treatments. The company is known for its innovative approach to chemotherapy, aiming to improve the efficacy and safety of existing cancer drugs.
Average Trading Volume: 50,289,696
Technical Sentiment Signal: Sell
Current Market Cap: $362.2K
See more data about NCNA stock on TipRanks’ Stock Analysis page.